## AMENDMENT OF THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions, and listings, of claims in the application.

- 1. (Currently amended) A method to reduce recruitment of <u>IDO+ dendritic cells</u> antigen presenting cells (APCs) that inhibit T-cell proliferation to at least one of a tumor or a tumor-draining lymph node a particular site in a subject comprising administering a composition comprising an antibody to CCR6 to the subject to reduce recruitment of the IDO+ dendritic cells to the at least one of a tumor or a tumor-draining lymph node, wherein the IDO+ dendritic cells express CCR6 and elevated levels of indoleamine 2,3-dioxygenase (IDO), and tumor cells of the at least one of a tumor or a tumor draining lymph node express MIP-3a IDO+ APCs or their precursors to the site, wherein the site is determined to comprise recruitment of IDO+ APCs, and wherein IDO+ APCs or their precursors are cells that express elevated levels of indoleamine 2,3-dioxygenase (IDO).
- (Canceled)
- 3. (Original) The method of claim 1, wherein the subject is human.
- 4. (Currently amended) The method of claim 1, wherein the <u>CCR6 antibody</u> composition comprises a compound that blocks the interaction between the <u>CCR6 expressed</u> by the IDO+ dendritic cells and the MIP-3α expressed by tumor cells of the at least one of a tumor or a tumor draining lymph node a biological signal present at the site of APC recruitment and a protein expressed on the surface of the IDO+ antigen-presenting cells (APCs) or their precursors.
- (Currently amended) The method of claim [[4]] 1, wherein the biological signal
  present at the site of APC recruitment comprises mip 3a further comprising the step of
  determining that IDO+ dendritic cells are recruited to the at the least one of a tumor or a
  tumor-draining lymph node.

(Currently amended) The method of claim 1 [[4]], wherein the MIP-3α mediates recruitment of the IDO+ dendritic cells to the at least one of a tumor or a tumor draining lymph node protein expressed on the surface of the IDO+ antigen presenting cells (APCs) or their precursors comprises a chemokine receptor.

Claims 7-48 (Canceled)